In the sandbox: palliative care and hematologic malignancies

Area of Science:

• Oncology
• Palliative Care
• Hematologic Malignancies

Background:

• Palliative care specialists are infrequently involved in managing patients with hematologic malignancies.
• These patients experience substantial symptom burden and often have incurable or poor-prognosis conditions.
• Hematologic malignancies, such as acute myeloid leukemia (AML) in older adults, have survival rates comparable to other cancers where palliative care is standard.

Purpose of the Study:

• To explore the reasons behind the limited integration of palliative care in hematologic malignancy treatment.
• To highlight the discrepancy in palliative care utilization between hematologic malignancies and other advanced cancers like pancreatic cancer.
• To advocate for increased palliative care involvement in hematologic oncology.

Main Methods:

• This study is a conceptual analysis and literature review.
• It examines the current state of palliative care involvement in hematologic malignancies.
• It compares this to palliative care integration in other advanced cancers with similar prognoses.

Main Results:

• There is a notable lack of palliative care involvement in hematologic malignancy patient care.
• The reasons for this underutilization remain unclear.
• Patients with hematologic malignancies, particularly AML over age 60, face prognoses similar to pancreatic cancer patients, yet receive less palliative support.

Conclusions:

• The limited involvement of palliative care in hematologic malignancies is not justified by clinical need or prognosis.
• There is a need to re-evaluate and increase the integration of palliative care services for patients with hematologic malignancies.
• Addressing this gap can improve symptom management and quality of life for these patients.